Category
Blog
-
2023
-
FDA Green Lights Clinical Trial of Low-Dose Psilocybin
-
Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1
-
US FDA declines to approve AbbVie’s Parkinson’s disease therapy
-
FDA Approves Evkeeza for Kids With Ultra-Rare Cholesterol Disorder
-
EU Authorizes Dupixent for Young Kids With Severe Atopic Dermatitis
-
FDA Approves Rezzayo, a Novel Echinocandin
-
FDA Approves Sandoz’s Citrate-Free Adalimubab Formulation
-
AbbVie Hits Snag for Parkinson’s Disease Candidate
-
AstraZeneca and Ionis build case for amyloidosis drug eplontersen
-
FDA Approves First-Ever Treatment for Activated Phosphoinositide 3-Kinase Delta Syndrome